InvestSMART

Orthocell Limited (ASX: OCC) - Announcements

Current share price for OCC : $0.795 0.005 (0.63%)+

ASX company news and announcements for Orthocell Limited (OCC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Orthocell Limited (OCC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Orthocell Limited (OCC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Orthocell Limited (OCC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$217 Orthocell Canaccord Genuity Conference Live Webcast 12 Aug 2026 8:27AM $0.800 $0.795 fallen by 0.63%
$217 Orthocell to Present at Canaccord Growth Conference 11 Aug 2026 8:45AM $0.730 $0.795 risen by 8.90%
$217 Change of Registered Office & Principal Place of Business 3 Aug 2026 8:38AM $0.730 $0.795 risen by 8.90%
$217 Appendix 3Y - John Van Der Wielen 20 Jul 2026 6:10PM $0.720 $0.795 risen by 10.42%
$217 Application for quotation of securities - OCC 20 Jul 2026 6:06PM $0.720 $0.795 risen by 10.42%
$217 Appendix 3Y x 4 17 Jul 2026 4:42PM $0.725 $0.795 risen by 9.66%
$217 Application for quotation of securities - OCC 17 Jul 2026 4:36PM $0.725 $0.795 risen by 9.66%
$217 Notification regarding unquoted securities - OCC 17 Jul 2026 1:31PM $0.730 $0.795 risen by 8.90%
$217 Notification regarding unquoted securities - OCC 17 Jul 2026 1:30PM $0.730 $0.795 risen by 8.90%
$217 Option Terms and Conditions 17 Jul 2026 10:07AM $0.753 $0.795 risen by 5.65%
$217 Proposed issue of securities - OCC 17 Jul 2026 10:03AM $0.753 $0.795 risen by 5.65%
$217 Notification of cessation of securities - OCC 16 Jul 2026 1:43PM $0.755 $0.795 risen by 5.30%
$217 Q4 FY26 ASX Investor Presentation 14 Jul 2026 8:47AM $0.850 $0.795 fallen by 6.47%
$217 Quarterly Activity Report & Appendix 4C 13 Jul 2026 8:53AM $0.845 $0.795 fallen by 5.92%
$217 Orthocell Investor Webinar Details 6 Jul 2026 8:43AM $0.755 $0.795 risen by 5.30%
$217 Orthocell Appoints Thailand Distributor for Remplir 3 Jul 2026 8:56AM $0.720 $0.795 risen by 10.42%
$217 Clinical Outcomes See Expanded Use of Remplir in the Ukraine 30 Jun 2026 8:51AM $0.725 $0.795 risen by 9.66%
$217 Cleansing Notice 14 May 2026 4:15PM $0.830 $0.795 fallen by 4.22%
$217 Application for quotation of securities - OCC 14 May 2026 4:11PM $0.830 $0.795 fallen by 4.22%
$217 Cleansing Notice 5 May 2026 4:22PM $0.855 $0.795 fallen by 7.02%
$217 Application for quotation of securities - OCC 5 May 2026 4:19PM $0.855 $0.795 fallen by 7.02%
$217 Appendix 3Y - Michael McNulty 4 May 2026 9:39AM $0.900 $0.795 fallen by 11.67%
$217 Appendix 3Y - John Van Der Wielen 4 May 2026 9:36AM $0.900 $0.795 fallen by 11.67%
$217 First Sales of Remplir Achieved in US$75m Canadian Market 30 Apr 2026 9:14AM $0.880 $0.795 fallen by 9.66%
$217 Compelling 90% Success Rate for Remplir in Real World Study 28 Apr 2026 9:10AM $0.850 $0.795 fallen by 6.47%

1 - 25 of 762 results

Page 1 of 31

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.